Wellington Management Group LLP Decreases Position in IDEXX Laboratories, Inc. $IDXX

Posted by Stanley Muller on Aug 30th, 2026

Wellington Management Group LLP trimmed its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 1.2% in the 2nd quarter, Holdings Channel.com reports. The firm owned 726,695 shares of the company’s stock after selling 8,780 shares during the period. Wellington Management Group LLP’s holdings in IDEXX Laboratories were worth $382,561,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Elyxium Wealth LLC bought a new position in shares of IDEXX Laboratories during the 4th quarter valued at approximately $3,666,459,000. J. Stern & Co. LLP lifted its position in IDEXX Laboratories by 23,694.7% in the fourth quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock worth $1,795,072,000 after buying an additional 2,642,200 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in IDEXX Laboratories by 63,503.9% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock worth $977,210,000 after buying an additional 1,442,174 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in IDEXX Laboratories during the second quarter worth $628,223,000. Finally, Norges Bank purchased a new position in IDEXX Laboratories during the fourth quarter worth $332,265,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Trading Up 1.8%

IDXX stock opened at $554.99 on Friday. The company has a market capitalization of $43.72 billion, a PE ratio of 39.03, a P/E/G ratio of 2.96 and a beta of 1.54. IDEXX Laboratories, Inc. has a 12 month low of $518.55 and a 12 month high of $769.98. The firm’s 50-day moving average is $559.01 and its 200 day moving average is $573.80. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, beating analysts’ consensus estimates of $3.94 by $0.33. The company had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The firm’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter last year, the business posted $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, research analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Barclays reduced their target price on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 11th. Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday. Citigroup upped their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. UBS Group increased their price objective on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 5th. Finally, Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Six equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and an average target price of $747.00.

Get Our Latest Stock Report on IDEXX Laboratories

About IDEXX Laboratories

(Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.